Clearmind Medicine (CMND) said late Monday that it applied for an international patent application for its combination therapy of N-Acylethanolamines and Ibogaine, which is considered a potentially effective anti-addiction agent.
The application follows developments in collaboration with SciSparc (SPRC). The companies are researching new combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, Clearmind said.
The company's shares were up more than 2% in after-hours activity, while SciSparc (SPRC) jumped 16%.
Price: 1.3600, Change: +0.03, Percent Change: +2.26
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments